The IMPAACT network is funded by the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health, all part of NIH. The P1107 study is conducted by the IMPAACT Network, in collaboration with the Center for International Blood and Marrow Transplant Research, StemCyte, and the NIAID-funded AIDS Clinical Trials Group.
Approval Marks Pivotal Expansion of HIV Prevention Options in the United States The U.S. Food and Drug Administration has announced its first approval of a long-acting HIV prevention medication, marking a pivotal expansion of HIV prevention options in the United… Read More ›
“The development of a safe and effective vaccine to prevent HIV infection has proven to be a formidable scientific challenge,” said NIAID Director Anthony S. Fauci, M.D.
Experts say by addressing the health disparities the EHE goals remain attainable and important, even as the COVID-19 pandemic presents new challenges and exacerbates existing health disparities.
An investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks safely and effectively prevents HIV acquisition in men who have sex with men and transgender women who have sex with men.
The world now has more young people than ever before – of the 7.2 billion people worldwide, over 3 billion are younger than 25 years, making up 42% of the world population. Around 1.2 billion of these young people are adolescents aged between 10 and 19 years.
A new commentary from National Institutes of Health scientists asserts that engaging men in HIV prevention and care is essential to the goal of ending the HIV pandemic.